Literature DB >> 9052857

Building up the family of ITIM-bearing negative coreceptors.

M Daëron1.   

Abstract

The acronym (ITAM) for immunoreceptor tyrosine-based activation motif was first proposed in September 1994, during the 8th Meeting on Signals and Signal Processing in the Immune System held in Kecskemet, Hungary, to designate the di-tyrosine-based YxxL activation motifs that had been previously understood by Michael Reth to account for the cell-triggering properties of BCR, TCR and FcR. It was then agreed, by those who signed the collective letter John Cambier had been commissioned to submit to Immunology Today (Cambier, J.C. (1994) Immunol. Today 16, 110-110) that it was premature to propose ITIM (for immunoreceptor tyrosine-based inhibition motif) to designate the one inhibitory sequence containing a single Ys1L motif that had been identified in the intracytoplasmic domain of a low-affinity Fc receptor for IgG. Right away, ITAM became unanimously accepted and widely used in the literature. Remarkably, ITIM was soon adopted too and, in September 1996, a whole session of the 9th Signal Meeting, held in Tihany, Hungary, was devoted to ITIM. During the last 2 years, evidence accumulated that indeed accredited the ITIM concept.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9052857     DOI: 10.1016/s0165-2478(96)02652-1

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  4 in total

1.  Dok-3, a novel adapter molecule involved in the negative regulation of immunoreceptor signaling.

Authors:  S Lemay; D Davidson; S Latour; A Veillette
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

2.  A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation.

Authors:  Daocheng Zhu; Christopher L Kepley; Min Zhang; Ke Zhang; Andrew Saxon
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

3.  Bovine leukemia virus SU protein interacts with zinc, and mutations within two interacting regions differently affect viral fusion and infectivity in vivo.

Authors:  Jean-Stéphane Gatot; Isabelle Callebaut; Carine Van Lint; Dominique Demonté; Pierre Kerkhofs; Daniel Portetelle; Arsène Burny; Luc Willems; Richard Kettmann
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

4.  Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19.

Authors:  Dániel Szili; Marcell Cserhalmi; Zsuzsanna Bankó; György Nagy; David E Szymkowski; Gabriella Sármay
Journal:  MAbs       Date:  2014-04-23       Impact factor: 5.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.